17 June 2015

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, will hold its Annual General Meeting in London later today.

At the meeting, Futura's Chairman, John Clarke, will make the following statement:

"During the year to date, Futura has continued to progress its product portfolio in line with the Company's plans for the commercialisation of its assets.

"On CSD500, our novel condom, we are continuing to work on a modified manufacturing process to extend the product's shelf life to meet condom industry requirements. While further testing is ongoing we are encouraged by the preliminary accelerated testing data received so far and remain on track for a regulatory filing of an extended shelf life product later this year.

"The clinical study of our diclofenac, ibuprofen and methyl salicylate topical gels began in March 2015 and we expect the headline results by the middle of next month. We are also at an advanced stage of preparations for our clinical study of MED2002 in erectile dysfunction.

"We have strengthened our development and production capabilities in the past year by more than doubling the number of full-time scientific and technical personnel to seven and by creating two separate teams, one for clinical development and one for chemistry, manufacturing and controls (CMC). The two teams are headed by experienced industry executives who report directly to the Company's CEO. This structure, and the strength of our balance sheet, will support us in the execution of our business plan."

 

For further information please contact:

Futura Medical plc
James Barder, Chief Executive
+44 (0) 1483 685 670
james.barder@futuramedical.com
www.futuramedical.com

Nominated Adviser:
N+1 Singer
Aubrey Powell / Liz Yong / Thomas Smale
Tel: +44 (0) 20 7496 3000

For media enquiries please contact:

Buchanan Communications Limited
Mark Court / Sophie Cowles /
Stephanie Watson
Tel: +44 (0) 20 7466 5000

 

Notes to editors:

About Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com